CRISPR Therapeutics, a biotechnology company focused on developing gene-editing medicines. The Wikipedia entry offers a comprehensive overview of the company, detailing its founding in 2013 by individuals including Nobel laureate Emmanuelle Charpentier, its headquarters in Switzerland, and its public listing on NASDAQ. It highlights key collaborations with companies like Vertex Pharmaceuticals and mentions their lead product, exa-cel (CASGEVY™), which received FDA approval in December 2023 for sickle cell disease and beta thalassemia. The official company website reinforces these points, emphasizing their decade of innovation and diverse pipeline spanning hemoglobinopathies, oncology, autoimmune diseases, and regenerative medicine, while also touting exa-cel as the first-ever approved CRISPR-based therapy. Both sources collectively portray CRISPR Therapeutics as a pioneer in gene-editing technology, committed to transforming patient lives through groundbreaking therapies.

Podcast creator page: http://santarovich.tilda.ws/

Support our podcast with your donations: https://paypal.me/OlgaSantarovich